REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology

Corporate News

Yokohama, Japan / Suzhou, China – July 27, 2026 – REPROCELL Inc., a global provider of clinical-grade iPSC technologies and regenerative medicine solutions, today announced a strategic collaboration with WEIPU Biotechnology Co., Ltd., a biotechnology company based in Suzhou, China, to support cell therapy developers in China with access to high-quality clinical starting materials and…

REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

Corporate News

JAPAN, June 24, 2026 – REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with…

Bioserve – A REPROCELL Company Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Corporate News

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…

Bioserve – A REPROCELL COMPANY Launches StemEdit: Clinical Gene Editing Services and New iPSC Lines Using AI-Designed Editing System

Corporate News

January 28th, 2026 – REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines leveraging OpenCRISPR-1™, an AI-designed genome editing system licensed from Profluent (Emeryville, CA, USA). StemEdit encompasses REPROCELL’s proprietary clinical gene-editing technology and its new gene-edited iPSC lines that are ready for immediate use. These offerings combine REPROCELL’s StemRNA™ Clinical…

REPROCELL and Histocell have achieved GMP certification for their manufacturing process of clinical-grade iPSC master and working cell banks using StemRNA™ Clinical iPSCs, ensuring high-quality and safe production for regenerative medicine applications.

Corporate News

Yokohama, Japan / Bilbao, Spain – October 20th — REPROCELL (Yokohama, Japan; TYO: 4978) and Histocell (Bilbao, Spain) are proud to announce that the Spanish Agency for Medicines and Medical Devices (AEMPS), operating under European Medicines Agency (EMA) oversight, has granted to Histocell Good Manufacturing Practice (GMP) certificate and authorization of the manufacturing process of induced Pluripotent…

REPROCELL Unveils Cutting-Edge Neoantigen Detection Service to Propel Precision Cancer Immunotherapy

Corporate News

Yokohama, Japan, August 20, 2025 REPROCELL is proud to announce the introduction of NeoSight – Neoantigen Detection Service, a state-of-the-art, end-to-end platform designed to empower researchers and clinicians with high-confidence neoantigen data for personalized immuno-oncology applications. This service integrates Next Generation Sequence (NGS) data obtained from whole exome sequencing (WES) of tumor and matched normal…

REPROCELL and Durham University Researchers Develop iPSC-Derived Full-Thickness Human Skin Model

Corporate News

Glasgow, UK — Scientists from REPROCELL Europe, working in collaboration with researchers at Durham University, have successfully developed a full-thickness human skin model using fibroblasts derived from induced pluripotent stem cells (iPSCs). The breakthrough, published in Cells (14(14):1044, 2025), demonstrates a novel approach to producing consistent, high-quality human skin constructs for research and therapeutic applications. Current skin models…

Notice Regarding Announcement by Partner Steminent Biotherapeutics Inc. of Phase II Clinical Trial Results in Taiwan for Spinocerebellar Ataxia Treatment “Stemchymal®”

Corporate News

YOKOHAMA, Japan – April 25, 2025 – REPROCELL Inc. today announced that its partner, Steminent Biotherapeutics Inc. (Headquarters: Taiwan; hereinafter “Steminent”), reported positive results on April 24, 2025, from Phase II clinical trials conducted in Taiwan and Japan for the stem cell therapy “Stemchymal®” (hereinafter “Stemchymal”). REPROCELL holds the exclusive commercialization license agreement for Stemchymal in…

World’s First Live Birth Using REPROCELL’s StemRNA Clinical Seed iPSCs for Oocyte Maturation Outside of the Body

Corporate News

REPROCELL is thrilled to celebrate a groundbreaking milestone by our partner Gameto, who recently announced the birth of the first baby born using Fertilo, a proprietary in vitro oocyte maturation technology. This major medical advancement marks a pivotal breakthrough in redefining women’s healthcare, supported by our StemRNA™ Clinical induced Pluripotent Stem Cells (iPSCs).